Compare ADMA Biologics Inc (ADMA) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Northrop Grumman Corporation — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Northrop Grumman Corporation trades at $544.81 (market cap $77.98B). The key difference: Northrop Grumman Corporation is far larger — about 36.6× ADMA Biologics Inc's market cap, and Northrop Grumman Corporation pays a 1.71% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | NOC | |
|---|---|---|
Market Cap | $2.13B | $77.98B |
Sector | Health | Industrials |
52-Week High | $20.38 | $768.02 |
52-Week Low | $7.60 | $496.02 |
Enterprise Value | $2.20B | $92.21B |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Northrop Grumman (NOC) trades at $549.04, showing minimal daily movement. The stock exhibits a bullish technical trend, supported by strong fundamentals including a 10.8% net income margin and consistent earnings beats. Recent news highlights contract wins and positive defense sector sentiment. Analyst consensus is strongly bullish with a $694.40 price target, indicating significant upside potential from current levels.
The outlook remains positive given the company's $95.61B backlog and stable cash flow generation. Key risks include political budget uncertainty and execution challenges. With solid institutional support and improving profitability metrics, NOC presents a compelling opportunity for investors seeking defense sector exposure, though geopolitical developments require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
